Fusion Pharmaceuticals — Investor Presentation (January 2024)
26 slides from Fusion Pharmaceuticals's investor presentation, Jan 4, 2024
Slide 1: Corporate Presentation January 2024
Corporate Presentation January 2024 Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements that are based on our management's belief and assumptions and on information currently avai
Slide 3: Fusion is a Leader in the Radiopharmaceutical Space
Fusion is a Leader in the Radiopharmaceutical Space Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved 3 Positioned to be first Ac-PSMA targeted radiotherapy to market for treatment of post-lutetium mCRPC, if approved; achieved alignment with FDA on potential registration pathway Lead
Slide 4: Lead Program: FPI-2265
Lead Program: FPI-2265 Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved
Slide 5: FPI-2265 is Currently the Most Advanced Actinium-Based PSMA Targeted Radiotherapy in Development
FPI-2265 is Currently the Most Advanced Actinium-Based PSMA Targeted Radiotherapy in Development More than 300 patients treated with 225Ac-PSMA globally, including ~100 post-177Lu-PSMA Achieved clinical POC in mCRPC Safety results supportive of developability (manageable hematological toxicity and x
Slide 6: Target Enrollment Complete in TATCIST Study: Data Readout Anticipated in April 2024
Target Enrollment Complete in TATCIST Study: Data Readout Anticipated in April 2024 Generally consistent with previously published data PSA50 response: ~30-50% Mix of patients who are pre- and post-lutetium, with majority naïve to Pluvicto Safety profile mostly limited to manageable xerostomia (Grad
Slide 7: Fusion Aligns with FDA on Potential Registrational Pathway
Fusion Aligns with FDA on Potential Registrational Pathway Phase 2/3 Study Initiation Expected in Q2 2024 Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved 2:1 50kBq/kg every 4 weeks 75kBq/kg every 6 weeks 100kBq/kg every 8 weeks FPl-2265 Recommended Regimen ARAT Switch 1:1:1 Randomiz
Slide 8: Potential FPI-2265 Market Opportunity in PLUVICTO Patients
Potential FPI-2265 market opportunity: Significant and Rapidly Growing Market in PLUVICTO™ Patients Expands Potential FPI-2265 Opportunity Source: VISION results per clinicaltrials.gov (NCT03511664); 177Lu-PSMA-617 radiographic ORR = 29.8%, mDOR = 9.8 mo.; PSA50 = 46%; duration of PSA response = 8.9
Slide 9: FPI-2265 Program Milestones
FPI-2265 Program Milestones Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Milestone Timing Preliminary TATCIST Data from approximately 25-30 Patients April 2024 Initiate Phase 2/3 Registration Study Q2 2024 Initiate Combination Trial with Olaparib 1H 2024 Completion of Phase 2 Stu
Slide 10: Actinium Supply & Manufacturing Capabilities
Actinium Supply & Manufacturing Capabilities Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved
Slide 11: Alpha-Emitting Radioisotopes Represent the Future of Radiopharma
Alpha-Emitting Radioisotopes Represent the Future of Radiopharma Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Double vs single strand DNA breaks create greater physical damage to cancer cells In preclinical studies, shorter range and higher energy transfer rates resulted in more
Slide 12: Fusion's Actinium Supply Designed to Provide Execution Advantage
Fusion’s Actinium Supply Designed to Provide Execution Advantage Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Clinical Site Ac-225 Generator On demand Ra-225 Fusion’s multiple strategic actinium supply agreements provide Preferential access and pricing to actinium Ability to scal
Slide 13: Fusion is Built on a Foundation of Radiopharmaceutical Manufacturing Expertise
Fusion is Built on a Foundation of Radiopharmaceutical Manufacturing Expertise Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Internal GMP manufacturing is fully operational: FPI-2265 (225AcPSMA) doses being shipped Clinical & potential commercial supply capabilities Capacity desig
Slide 14: Moving the Field Beyond Prostate and NETs: Fusion's Clinical-Stage Pipeline
Moving the Field Beyond Prostate and NETs: Fusion’s Clinical-Stage Pipeline Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved
Slide 15: Unlocking the Potential of Radiopharmaceuticals in Cancers Outside of Current Approved Indications
Unlocking the Potential of Radiopharmaceuticals in Cancers Outside of the Few Current Approved Indications Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Discovery Preclinical/ IND Enabling Phase 1 Phase 2 Phase 3 FPI-2265* FPI-1434* FPI-2059 FPI-2068 Solid Tumors Expressing IGF-1R
Slide 16: Fusion's Pipeline: Next Generation ADCs Using Lessons from PSMA
Fusion’s Pipeline: Next Generation ADCs Using Lessons from PSMA PSMA SMDC vs. PSMA RLT in mCRPC Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Morris et al. (2017) J Clin Oncol 35, suppl; abstr 5038 PSA Best % change from Baseline EC1169 (PSMA-tubulysin) Pluvicto (177Lu-PSMA-617) H
Slide 17: FPI-1434 Phase 1 Trial: A First-of-its-Kind Antibody-Based Targeted Alpha Therapy Study
FPI-1434 Phase 1 Trial: A First-of-its-Kind Antibody-Based Targeted Alpha Therapy Study for Solid Tumors Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved “Cold” IGF-1R Antibody “Hot” IGF-1R antibody: FPI-1434 FPI-1434: An IGF-1R antibody carrying 225Ac: Delivering DNA damaging alpha
Slide 18: Cohort in Cold+Hot Dosing Regimen Showed Promising Results that Supported Dose Escalation
Cohort 1 in Cold+Hot Dosing Regimen Showed Promising Results that Supported Dose Escalation In June 2023, Fusion reported data from the first cold+hot dosing cohort at 15 kBq/kg: No DLTs, limited to transient Grade 1 or less thrombocytopenia 2/3 patients showed stable disease; ovarian patient receiv
Slide 19: Encouraging Safety and Early Signals of Antitumor Activity at 25 kBq/kg
Encouraging Safety and Early Signals of Antitumor Activity at 25 kBq/kg Safety: 2 out of 3 patients completed DLT period No DLTs, limited to transient Grade 1 or less thrombocytopenia (comparable to 15 kBq/kg) Activity: One patient (chordoma) showed stable disease; received 4 cycles of therapy One p
Slide 20: Fusion's Early-Stage Pipeline
Fusion’s Early-Stage Pipeline Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved
Slide 21: Phase Ready Program: Next Generation ADCs with AstraZeneca Collaboration
Phase 1 Ready Program Non-Small Cell Lung Cancer Model Recognizing the Potential of TATs as Next Generation ADCs with AstraZeneca Collaboration Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Fusion’s FastClear™ Linker EGFR binding cMET binding Ac-225 First Program Under Our Multi-A
Slide 22: FPI-2059: A Small Molecule TAT Targeting Neurotensin Receptor 1 (NTSR1)
FPI-2059: A small molecule TAT targeting Neurotensin Receptor 1 (NTSR1) Currently in Phase 1 dose escalation Fusion acquired the small molecule 177Lu radiopharmaceutical, IPN-1087, from Ipsen Human imaging data Promising early clinical safety data 225Ac-IPN-1087 Shows Single Dose Tumor Kill In Precl
Slide 23: Fusion's Radiopharmaceutical & Oncology Drug Development Expertise
Fusion’s Radiopharmaceutical & Oncology Drug Development Expertise Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved CHIEF OF STAFF Cara Ferreira, PhD PRESIDENT & CBO Mohit Rawat CLO Maria Stahl, JD CSO Chris Leamon, PhD CEO John Valliant, PhD CTO Eric Burak, PhD CFO John Crowley, CPA
Slide 24: Unaudited Financials and 2024 Milestones
Unaudited Financials and 2024 Milestones Unaudited Financials Extended Cash Runway ~$287M* Pro Forma Cash, Cash Equivalents and Investments Cash to Fund Operations extended into Q4 2025 Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved *Pro forma 9/30/23 cash, cash equivalents and inv
Slide 25: Fusion is a Leader in the Radiopharmaceutical Space
Fusion is a Leader in the Radiopharmaceutical Space Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved 25 Achieved alignment with FDA on potential registration pathway Lead Program AcPSMA in Phase 2/3 Actinium & Manufacturing Advantages Creating Next-Generation ADCs GMP radiopharma man
Slide 26: Thank You
www.FusionPharma.com Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Thank You
Fusion Pharmaceuticals — Investor Presentation (January 2024) on 6ix